June 29, 2020 06:58 AM EDTUpdated 10:34 AM

Covid-19 roundup: Temasek leads a $250M raise for BioNTech as first Covid-19 mRNA vaccine data looms; China's military OKs first use of coronavirus vaccine

John Carroll

Editor & Founder

Singapore’s giant fund run by Temasek is putting some financial muscle behind BioNTech $BNTX as the Pfizer partner prepares to post the first cut of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Temasek leads a $250M raise for BioNTech as first Covid-19 mRNA vaccine data looms; China's military OKs first use of coronavirus vaccine

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus

Covid-19 roundup: Temasek leads a $250M raise for BioN­Tech as first Covid-19 mR­NA vac­cine da­ta looms; Chi­na's mil­i­tary OKs first use of coro­n­avirus vac­cine

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Covid-19 roundup: Temasek leads a $250M raise for BioNTech as first Covid-19 mRNA vaccine data looms; China's military OKs first use of coronavirus vaccine

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus